Investor Presentation First Nine Months of 2023
17
Investor presentation
First nine months of 2023
Strategic aspirations 2025
sustainability
(ESG)
Purpose and
খ
Commercial
execution
•
•
Progress towards zero environmental impact
Being respected for adding value to society
Being recognised as a sustainable employer
Strengthen Diabetes leadership - aim at global value
market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
CVD: Cardiovascular disease; MASH: Metabolic dysfunction-associated steatohepatitis; CKD: Chronic kidney disease.
Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.
Financials
Innovation and
therapeutic focus
Опш
•
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment
solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases
focusing on CVD, MASH and CKD
•
Deliver solid sales and operating profit growth
.
Drive operational efficiencies across the value chain to
enable investments in future growth assets
• Deliver free cash flow to enable attractive capital
allocation to shareholders
Novo NordiskⓇView entire presentation